Stevia extract or hair care steviol

FIELD: chemistry.

SUBSTANCE: invention refers to using an oral composition containing steviol, which improves the human hair or animal fur/feather/scale look. Using steviol in preparing the oral composition of nutriceuticals or a nutrient composition for improving the human hair or animal fur/feather/scale look.

EFFECT: invention provides improving the human hair or animal fur/feather/scale look more effectively.

7 cl, 4 dwg, 5 tbl, 13 ex

 

Area of technology

The invention relates to the use of oral compositions containing Stevia extract, steviol precursors (steviol glycosides) or free steviol, which improves the appearance of hair and prevents hair loss. It also relates to methods of improving the appearance of hair by oral administration of an effective amount of Stevia extract, steviol precursors or steviol.

The level of technology

Stevia rebaudiana is a plant that is known that contains sweet-tasting substances, including stevioside and rebaudioside A. These substances are usually used as a sugar substitute in some foods, including soft drinks. A detailed description of their safety, toxicology and metabolism can be found in Food and Chemical Toxicology (Food and Chemical Toxicology) 2008 vol 46(7), Supplement I, where all the app on the application of rebaudioside And in foods and beverages. Stevioside and rebaudioside And metabolize to the aglycone steviol, substances that do not have a sweet taste.

JP 10265347 (Shiseido Co., Ltd) describes an agent that prolongs the growth period of the hair cycle and can be obtained from some plant extracts including comfrey (Symphytum offionale L.), Curcuma domestica, the jujube tree (Zizyphus jujube), Keirin wild ginger (Asarum sieboldii), seeds coxa of bucenica (Coix lachrima), Stevia, cube �amber (Uncardiagambir roxburgh), gentian (Gentiana lutea), hops (Humulus lupus), Isodon Japonicicus, and adzuki beans (Azukia angularis) in addition to a number of other plants.

EP 1666036 describes a hair growth stimulant containing the compound of chromin, such as methyldiphenylamine And, acetovanillone or orthochromis. Chromenone compounds can be extracted from the species Stevia in addition to other plant species and varieties. Hominy related structurally with stevioside or Saviola.

A need exists to create compositions for hair care that can be entered orally and which can improve natural health and beauty of hair, and which can restore hair growth and prevent ageing-related hair loss/thinning.

Brief description of the invention

According to the present invention, it has been shown that continuous intake of oral compositions containing the steviol, steviol precursors (steviol glycosides) or Stevia extract, preferably containing stenosed and/or rebaudioside And (both of these compounds are physiologically metabolized to steviol in the gastrointestinal tract of mammals), leads to a surprising improvement in the appearance of hair/fur.

Thus, one embodiment of the invention is a method of improving the appearance of hair/fur/feathers/scales in animals, comprising administering an oral nutraceutical or �hideway compositions containing of steviol, a steviol precursor, such as a steviol glycoside, or a Stevia extract containing stenosed and/or rebaudioside And, for sufficient time and in an amount effective to improve the appearance of hair/fur/feathers/scales of the animal, and monitoring or evaluation.

Another embodiment of this invention is the use of steviol, of a steviol precursor, such as a steviol glycoside, or a Stevia extract containing stevioside and/or rebaudioside And in the production of an oral nutraceutical or food composition, which improve the appearance of hair/fur/feathers/scales in animals and especially the hair/fur in mammals.

It was also shown that the constant adding oral steviol restores the natural dark color of the fur in older mice, which are normally with age are gray fur. Thus, another aspect of the invention is a method of restoring hair color/fur and/or delay graying of the hair/fur. Another aspect of this invention is the use of steviol for the preparation of nutraceutical or food composition, which delay the formation of gray hair and/or restore hair color/fur. According to the present invention, it was also found that mammals, which had been of steviol or a Stevia extract containing stevioside and/or rebaudioside A, brushless�was ovalis less hair loss, than animals treated with placebo. Thus, another aspect of the invention includes a method:

reduce hair loss,

restore hair growth after baldness come,

increasing the thickness of the hair,

confrontation age thinning of hair,

prevent or reduce early baldness,

delay the onset or severity of age-related hair loss and/or

delay of onset or the severity of the thinning hair,

introducing oral dosage forms steviol, a steviol precursor, or a Stevia extract containing stevioside and/or rebaudioside A. According to yet another aspect of this invention, of steviol, a steviol precursor, or a Stevia extract, stevioside and/or rebaudioside And that is used in cosmetic oral composition to achieve the above objectives, including loss/thinning hair.

The compositions of the present invention is particularly attractive because many people, including those of animals and caring for animals, are especially interested in cosmetic treatment considered as "natural" with mild effects and without major side effects. Being orally available substances, Stevia extract and steviol have additional benefits, as they are easy to apply, they don't leave nick�their residue on the hair or fur, and easier to control the dosage, than at local application.

Brief description of figures

Figure 1. The impact of continuous processing Stevia extract (450 mg/kg per os, 8 weeks) on hair loss in mice C57B I/6J middle age. The results represent mean values (S. D., and the average indicator on the mouse obtained for animals treated with the extract posconnika (SE; n=12) and control mice treated with carrier (VEH); n=13). The Stevia extract has greatly improved (i.e. reduced) hair loss compared to control mice, ***p<0.001.

Figure 2 the Effect of continuous treatment Saviola (120 mg/kg, per os, 6 weeks) (a) color and (b) hair loss aged mice C57B I/6J. The results represent mean values (S. D. average on the mouse before and after treatment with Saviola (STEV; n=7 n=10). Of steviol has greatly improved hair color (i.e., reduced gray and has greatly improved (i.e. reduced) hair loss (before treatment-ultrasound after treatment: *p<0,05).

Figure 3 demonstrates the correlation between the level of free steviol in the plasma and phenotypic evaluation characterizing the prevention of hair loss given in Example 1.

Figure 4 shows the genes that are regulated by Saviola, which were subsequently mapped to biological processes with the application of statistical meth�Dov software Genedata package.

The Stevia extract containing stevioside and/or rebaudioside And the present invention can be prepared using known methods. This invention is not intended specifically for the use of Stevia extract as a sweetening agent for songs, where for the induction of improving the appearance or growth of hair/fur used ingredients other than the Stevia extract, stevioside rebaudioside and/or rebaudioside. In addition, Stevia extract according to the present invention does not contain a number of bioactive chromenew sufficient to stimulate the activity of hair growth.

Of steviol can be obtained by enzymatic hydrolysis of stevioside by the methods described in the literature. On the other hand, since steviol glycosides, such as stevioside and rebaudioside And metabolized to steviol can be used a plant extract containing and rebaudioside and/or stevioside. Preferably, the amount of steviol glycosides is large (>50%). However, these compositions have a very sweet aroma and aftertaste, so food it is desirable to add substances that mask or enhance the flavor.

Alternatively, the plant extract can be applied compositions containing the active ingredients stevioside or rebaudioside A. in contrast, in particular, if it improves the condition of hair active�second connection has to do with food, and the sweet taste is undesirable, it is possible to apply compositions containing the steviol. Especially preferred of steviol in the event of his application for restoration of hair color.

DEFINITION

Used in the application, the term "nutraceutical composition" includes food products, foods, dietary supplements, Supplement, or nutraceutical composition for adding to foods or food products, including drinks (e.g. drinks for sports, functional, water, juice, smoothies, instant drink, but not limited to, soups, dairy products (e.g. yoghurt drinks a single application, but not limited to, food concentrates and jams.

Used in the application, the term "food product" refers to any food or any food, suitable for ingestion by humans or animals.

Used in the application, the term "dietary Supplement" refers to a small amount of substance to add to the diet of a human or animal, packaged in single or multiple dosages. Dietary supplements usually do not provide significant calories, but may also contain other micronutrients (e.g. vitamins or minerals).

The term "nutritional Supplement" refers to a composition containing a dietary Supplement in combination�logical source of calories. In some embodiments, the nutritional supplements are food substitutions or additions (e.g., nutrient or energy concentrates or nutritional drinks or concentrates).

Used in the application, the term "prevention" is not intended to refer to events that will never happen, but it means a delay of the onset of the condition or event and reducing the severity of the condition or event if they occurred.

"Continuous introduction" means the regular introduction of the active ingredient for a considerable period of time, e.g., once or twice a day for at least two weeks, preferably within one month, and more preferably, at least within two months. On the other hand, perhaps regular infusions every two days or once a week or twice a week.

"Hair" means the hair of humans or fur of animals. This term may also include the feathers of birds and scales of fishes.

"Extended period" means almost daily for at least about two weeks, preferably for at least about one month, and even more preferably, for about two months.

"Steviol precursor" means a steviol glycoside, which can be enzymatically hydrolysed to free aglycone steviol. See, �of primer, EFSA Journal 2010, 8(4); 1537 included in this application by reference. Suitable for hydrolysis enzymes present in microorganisms, as well as in the intestinal tract of humans and animals. Cm. Gardans et al. 2003 J. Agric. Food Chem. 51: 6618-22 included in this application by reference.

"Stevia extract" according to the specification and the formula of the invention should be understood as the active ingredient, improve the condition of hair. Thus, it is either present as the sole active ingredient that improves the condition of hair, or, when used in combination with another ingredient, it is not intended to be a sweetener, and/or the amount of Stevia extract are not enough to sweeten the composition or food product, or it does not contain Hominy in the amount of stimulating hair growth.

"Observation" or "assessment" can be performed by persons who took an active ingredient, or may be performed by a third party. Condition after administration of the drug can be compared with the situation prior to the introduction of the drug, and it can be analyzed using the standard test, or by using subjective analysis.

"Improved" means that the quality of the hair/fur has improved at least one of the following:

color (i.e., the delay backup/restore natural color �about with respect to the gray),

alopecia (i.e. saved hair/fur, the hair loss stops or slows down; hair or re-grow),

the thickness of the hair/fur (thinning hair slows down, stops or turns),

the Shine of the fur (the fur no longer looks primed and seems more shiny),

sores/lesions on the skin are healing or have healed,

the Shine or luster of the hair/fur (hair/fur look less dull and more shiny/shiny).

Anti-Gray hair

More preferably, the present invention relates to the use of oral compositions containing the steviol or steviol precursors, for hair care, especially to prevent graying of the hair and/or restoring and/or maintaining the natural hair color. It refers also to introduce oral compositions for hair care, especially to prevent graying of the hair and/or restoring and/or maintaining the natural hair color containing Stevia extract or steviol or steviol precursor and a carrier that is conventionally used for oral nutraceutical or food compositions with the proviso that when present in combination with a second active ingredient, an extract of Stevia is not present in sufficient quantity to sweeten the composition. Furthermore, the invention relates to a method of preventing graying in�OS and/or restoring and/or maintaining the natural hair color, which includes the oral administration to a mammal in need of such treatment, a composition containing an effective amount of Stevia extract, steviol or steviol precursor and resulting in the prevention of hair graying and/or maintaining the natural hair color considering the fact that, being present in combination with a second active ingredient, an extract of Stevia is not intended for sweetening composition. For these methods, and applications particularly preferred of steviol.

Veterinary use

In another aspect of this invention Stevia extract was administered to animals, preferably mammals, but not humans. Since keratin compounds in your hair are improved as a result of application of this invention, the winning application of the invention is not limited to mammals and can spread to other animals such as birds or fish, or other animals, painting or improvement of the quality of which is of interest. For example, a bird may be home, of particular interest are those individuals who participate in demo contests. The increased color may be useful for fish, such as, for example, for a goldfish.

In a preferred aspect of this invention, the animal is not man, but a mammal, such as a pet (dog, cat, ferret) Il� animal used in the fur industry (mink, chinchilla, etc.), or animals exhibited in competitions (such as dogs, horses, cats, rabbits and other farm animals). Adding to the diet of animals Stevia extract, steviol or steviol precursor of the present invention will improve the appearance of animal fur. Thus, another aspect of this invention is a veterinary nutraceuticals or food product containing improves the fur amount of Stevia extract, steviol or steviol precursor.

Because some animals may not like the sweet taste of Stevia extract for veterinary use, it may be desirable that the extract contained of steviol and not predecessors steviol because of steviol does not have a specific taste.

Another aspect of this invention is a Supplement, especially indicated for animals demonstrated that Stevia extract, steviol or steviol precursor. Animals must obtain this Supplement daily for at least one month and preferably for at least two months before the competition, so his fur was in optimal condition. In preferred embodiments, the additive should be in the form of treats or chewing gum.

Preferred food products

A food product can be �prigotovlennoi and pre-packaged food (e.g., mayonnaise, salad dressing, bread or cheese) or animal feed (e.g., molded or granulated animal feed, coarse mixed feed, food compositions for animals, sweets or chewing gum).

Food or food is, for example, drinks such as soft drinks and alcoholic beverages, as well as liquid concentrates to be added to drinking water and liquid food. Soft drinks, for example, sugar water, sports drinks, fruit juices (e.g. orange juice, Apple juice and grapefruit juice; lemonades, teas, diluted drinks, milk and other dairy products (e.g. yogurt) and diet drinks. In another embodiment, foods, or foods refer to solid or semi-solid food containing the composition according to the present invention. These forms may include, but are not limited to, bakery products such as cakes and biscuits, puddings, dairy products, sweets, snack foods, or frozen sweets, or new types of products (e.g. ice cream, milk shakes), prepared from frozen food, candy, snack foods (e.g., chips or potato chips), liquid food such as soups, spreads, sauces, salad dressings, prepared masn�e products cheese, yogurt and any other containing fat or oil food and food ingredients (e.g., wheat flour).

Pet food, comprising a food composition for domestic animals, mainly contains food products designed to meet necessary dietary requirements, as well as treats (e.g., dog biscuits) or other food supplements. Animal feed containing the composition of the present invention may be in the form of a dry composition (e.g., pellets), semi-moist composition, wet composition, or mixtures thereof. Alternatively, or in addition animal feed is an additive, such as a gravy, drinking water, yogurt, powder, suspension, chew, treat (e.g., biscuits) or any other form supplied.

Dietary supplements of the present invention formulated for oral administration. The ingredients of dietary supplements of the present invention are contained in suitable excipients and/or carriers for oral administration. The current form of the carrier and, accordingly, the dietary Supplement itself is not critical. The carrier may be liquid, gel, gelatin capsule, capsule, powder, solid tablet (coated or not coated), tea or the like. Dietary Supplement preferably exists in the form of a tablet or capsule and most p�edocfile, in the form of a hard (shell) gelatin capsules. Suitable excipients and/or carriers include maltodextrin, calcium carbonate, dicalcium phosphate, microcrystalline cellulose, dextrose, rice flour, magnesium stearate, stearic acid, croscarmellose sodium, sodium starch glycolate, polyplasdone, sucrose, vegetable resin, lactose, methylcellulose, pavido, carboxymethyl methylcellulose, corn starch and other compounds (including mixtures thereof). Preferred carriers include calcium carbonate, magnesium stearate, maltodextrin and mixtures thereof. Different ingredients and excipients and/or carriers are mixed and formed into the desired shape using conventional methods. Tablets or capsules of the present invention can be coated with enteric coating which dissolves at a pH of from about 6.0 to about 7.0. Suitable enteric-coated, which dissolves in the small intestine, but not in the stomach, is cellulose acetate phosphate. Additional details of methods of education and administration can be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

In other embodiments, a dietary Supplement is supplied in the form of powder or fluids that are suitable for adding a consumer in food or drink. For example, in some embodiments the dietary Supplement, you can enter the individual�mu in the form of powder, for example, for mixing with the beverage or stirring in semi-solid food, such as pudding, gravy, sauce, mashed potatoes, porridge or salad dressing, or, conversely, adding in food, for example, enclosing it in a cover or receptacles for beverage to release the additive immediately before use. Dietary supplements may contain one or more inert ingredients, especially if you want to limit the number of calories added to the diet dietary Supplement. For example, the dietary Supplement of the present invention may also contain arbitrary ingredients, such as herbs, vitamins, minerals, enhancers, colorants, sweeteners, flavorings, inert ingredients, and similar substances.

In some embodiments, dietary supplements also contain vitamins and minerals, including, but not limited to, tribasic calcium phosphate or calcium acetate; potassium phosphate, dibasic; sulfate or magnesium oxide; salt (sodium chloride); chloride or potassium acetate; ascorbic acid; iron orthophosphate; Niacinamide; sulfate or zinc oxide; calcium Pantothenate; copper gluconate; Riboflavin; beta-carotene; pyridoxine hydrochloride; thiamine Mononitrate; folic acid; Biotin; chloride or picolinate chromium; potassium iodide; sodium selenate; sodium molybdate; phylloquinone; vitamin D3; cyanocobalamin;sodium Selenite; copper sulphate; vitamin a; vitamin C; Inositol; potassium iodide.

In other embodiments, the invention supplies a nutritional Supplement (that is, the energy concentrates or concentrates, write or replacement drinks) containing a composition of the present invention. A nutritional Supplement may serve as a Deputy of meals or snacks and in General, providing food calories. Preferably, nutrient additives supply carbohydrates, proteins and fats in balanced quantities. A nutritional Supplement can also contain simple carbohydrates with an average chain length or polysaccharides, or a combination. Simple sugar can be selected to achieve the desired organoleptic effects. One example of a complex carbohydrate is uncooked cornstarch. If you want to keep a structure corresponding to high molecular weight, it should be enabled only in food such structures or portions which are not subjected to heat treatment, because it will destroy the complex carbohydrates to simple carbohydrates, namely, to mono - and disaccharides. In one embodiment, the nutritional Supplement contains a combination of sources of carbohydrates with three levels of values of the chain length (simple, average and complex; for example, sucrose, maltodextrins, and uncooked cornstarch).

Sources of protein, which should� to be included in the nutritional Supplement of the present invention, can be any suitable proteins used in nutritional compositions and may include whey proteins, concentrate protein whey powder from whey, eggs, soy flour, soy milk, soy protein isolated soy protein, Caseinate (e.g. sodium Caseinate, sodium Caseinate and calcium, calcium Caseinate, potassium Caseinate), animal and vegetable proteins and hydrolysates their mixtures. When choosing a protein source should first consider the biological value of the protein with the highest biological value was found in Caseinate, whey, lactalbumin, egg albumin proteins and whole eggs. In a preferred embodiment, the protein is a combination of a concentrate of whey proteins and calcium Caseinate. These proteins have a high biological value; that is because they have a high proportion of essential amino acids. Cm. Modem in Health and Nutrion Dsease, Eighth Edition, Lea & Febiger, publishiers, 1986, especially Volume 1, pages 30-32.

A nutritional Supplement can also contain other ingredients such as one or a combination of other vitamins, minerals, antioxidants, fiber and other dietary supplements (e.g., protein, amino acids, choline, lecithin, omega-3 fatty acids). Selecting one or more of these ingredients depends on the preparation, design, user and preferences of end-uses�to the user. The amounts of these ingredients included in the food additive of the present invention, well known to experts. The guide for determining such quantities can be ensured by US RDA doses for children and adults. Also, adding vitamins and minerals include, but are not limited to, phosphate or calcium acetate, tribasic; potassium phosphate dibasic; sulfate or magnesium oxide; salt (sodium chloride); chloride or potassium acetate; ascorbic acid; iron orthophosphate; Niacinamide; sulfate or zinc oxide; calcium Pantothenate; copper gluconate; Riboflavin; beta-carotene; pyridoxine hydrochloride; thiamine Mononitrate; folic acid; Biotin; chloride or picolinate chromium; potassium iodide; sodium selenate; sodium molybdate; phylloquinone; vitamin D3; cyanocobalamin; sodium Selenite; copper sulphate; vitamin a; vitamin C; vitamin E, Inositol; and iodide of potassium. Moreover, multivitamin and mineral supplements can be added to nutritional compositions of the present invention to obtain adequate quantities of essential ingredients that are missing in some diets. Multivitamin and mineral supplements can also be used to prevent diseases and to protect against nutritional deficiencies and deficits caused by the nature way of life.

Nutritional supplements may come in a different form� and be made in different ways. In a preferred embodiment, for the production of food concentrate used liquid ingredients; add dry ingredients to liquid ingredients into the mixture and stirred to obtain a dense mass. Paste is put into the extruder and push out; subjected to extrusion mass is cut into specific lengths; and cooling the product. The concentrate can contain other nutrients and fillers to improve the taste, in addition to the specific ingredients listed in the application.

Experts understand that other ingredients, such as fillers, amplificatori, fuses, etc. can be added to listed in the application for the development and manufacture of nutritional supplements.

In addition, nutritional supplements may be included flavorings, coloring agents, spices, nuts and similar compounds. Flavors can be applied in the form of aromatic extracts, volatile oils, chocolate fragrances, flavors based on peanut butter, bread crumbs, light rice, vanilla or any commercially available flavoring. Examples of useful flavorings include, but are not limited to pure anise extract, imitation banana extract, imitation cherry extract, chocolate extract, pure lemon extract, pure orange extract, pure PE�jwc extract imitation pineapple extract, imitation rum extract, imitation strawberry extract, or pure vanilla extract, or volatile oils, such as lemon oil, Bay oil, bergamot oil, cedar oil, walnut oil, cinnamon oil, clove oil or peppermint oil; peanut butter, chocolate flavoring, vanilla crumb, butterscotch or toffee. In one embodiment the dietary Supplement contains cocoa or chocolate.

For the stability of the food additives can be added amplificatory.

Examples of suitable emulsification include, but are not limited to, lecithin (from egg or soy) and/or mono - and diglycerides. Well-known professionals other amplificatory, and the choice of the appropriate(s) emulsifier(s) will depend in part on the composition and end product. To increase the storage time of the product to the food additive may be added also the fuses. Preferably used as such preservatives like potassium sorbate, potassium sorbate, sodium, potassium benzoate, sodium benzoate or calcium disodium EDTA.

Besides the above-mentioned carbohydrates, the nutraceutical composition may contain natural or artificial (preferably low calorie) sweeteners, such as sugars, cyclamate, aspartame, aspartame, Acesulfame K and/or sorbitol, is not limited�EVAs them. Such artificial sweeteners can be desirable if a dietary Supplement is for individuals who are overweight or obese or those with type II diabetes who are at risk for hyperglycemia.

Dosage

Recommended for people and animals dosage of Stevia extract are in the range from 0.1 to 500 mg/kg of body weight per day, preferably from 0.5 to 250 mg/kg of body weight per day, and more preferably, from 1.0 to 50 mg/kg of body weight per day.

The preferred dosage of steviol are in the range of from 0.01 to 100 mg/kg of body weight per day, preferably from 1.0 to 50 mg/kg of body weight per day and more preferably, from 0.5 to 25 mg/kg of body weight per day and/or from 0.5 to 10 mg/kg of body weight per day.

The preferred dosage of steviol precursors are in the range from 0.05 to 1000 mg/kg of body weight per day, preferably from 0.5 to 500 mg/kg of body weight per day and more preferably, from 1.0 to 100 mg/kg of body weight per day.

The preferred daily dosage described above-discussed compositions can be administered in one or two metered units, such as tablets. Most preferably, a daily dosage of discussing the composition is introduced by one unit twice a day or two units that are taken twice a day, only four units per day. Compared with taking the entire daily dose RA� a day twice daily dosage is in the form of one or more units per dose promotes better absorption and better maintain the level of essential ingredients in the blood. In the case of Stevia extract or predecessors Savilov dosage at the reception is from 30 to 1000 mg, for steviol from 10 to 500 mg.

For use in humans and animals recommended dose of steviol glycosides is in the range of 0.05 mg per kg of body weight to about 100 mg per kg of body weight per day. More preferably, a daily dose of from about 0.1 to 20 mg per kg of body weight and especially preferred is a daily dosage from about 0.1 to 20 mg mg per kg of body weight and especially preferred is a daily dosage from about 1.0 to 10.0 per kg of live weight.

Recommended levels in foods

Category foodThe predecessor of steviol (steviol glycoside, for example, Rebaudioside A or stevioside) mg/kg foodThe predecessor of steviol (of steviol (steviol glycoside) mg per doseFree of steviol mg/kg foodFree of steviol mg per dose
Cereals (oat flour, corn pellets50-10002-40/40 g 250-75010-30/40 g
Ready tea20-4805-120/0.25 l20-2005-50/0.25 l
Fruit juices50-60012,5-150/0,25 l30-2005-100/0.25 l
Dietary malalcahuello drinks50-60012,5-150/0,25 l30-2005-50/0.25 l
Energy drinks50-60012,5-150/0,25 l20-60030-150/0.25 l
Aromatic beverages20-4005-100/0.25 l20-12005-30/0.25 l
Small bakery Products50-10002-40/40 g250-75010-3 0/40 g
Confectionery1000-600020-120/20 g5-20/20 g

In a preferred embodiment, the Stevia extract or steviol or steviol precursor containing nutraceuticals or food that is eaten regularly, i.e. at least daily for a constant period of time (i.e. at least one week, preferably at least two weeks and preferably within three weeks or at least one or two months) until it becomes noticeably healthier hair. After that, the user can reduce the dose.

The following non-limiting examples are presented to better illustrate the invention.

Example 1

The constant processing of Stevia extract to the condition of the fur and skin of wild type mice middle aged.

Mice C57B 1/6J middle-aged (18 months) was administered Stevia extract (450 mg/kg, p. O.) or vector (a 1:1 mixture of water with corn oil) daily for eight weeks.

By the end of the treatment period mice were anestesiologi (2,2-2,4% isofluorane) and each mouse was photographed. Interviewed eight participants with extensive experience in experimental work with mice, inviting them to evaluate the subjective condition of the fur and skin of each mouse on a threelevel scale (Cm. Table 1). The parameters for assessing the quality of fur included a color of fur, loss of hair, the luster (gloss) and General appearance (well-groomed/groomed�th); for the assessment of a skin condition participants were required to rate the appearance of the sores. Averages for each mouse received 8 individual readings participants were then allowed to compare mice treated with Stevia extract and control mice treated with the vector.

As can be seen in Figure 1, treatment Stevia extract significantly reduced the degree of hair loss as compared to the control mice, as shown by higher subjective assessment of this parameter (p<0.01, unpaired t-test).

Table 1
The system for evaluating the condition of fur and leather
Fur color
Grizzled and old 1Not evident 2Dark and young 3
Baldness/hair loss
Significant hair loss 1Partial hair loss 2Normal hair 3
Shiny fur
Dull fur 1Not evident 2Shiny and healthy 3
Appearance fur
Ragged, unkempt 1Not evident 2Well maintained 3
Visible wounds/damage
Lot 1Little 2No 3 /

Example 2

The effect of continuous treatment Saviola to the condition of the fur and skin of wild type mice older

In female mice C57B 1/6J older (22-24 months) were assessed by the quality of fur at the beginning and at the end of the six-week study. Before processing the photos were taken all the mice while they were under light anesthesia (2,2-2,4% of isofluorane). The mice then received either placebo or a diet enriched with Saviola (120 mg/kg/day) for six weeks. By the end of phase six-week treatment of mice reiterated anestesiology and made new pictures.

Interviewed eleven participants with extensive experience in experimental work with mice, offering them to fill in the same questionnaire (See Table 1) for subjective assessment of a number of parameters characterizing the quality of fur and sores on the skin, comparing pictures before and after treatment.

Statistical analysis was performed using Prism 5 (Programs�th GraphPad software,La Jolla, CA, USA) using, if necessary, Bonferroni post-hoc test.

Of steviol has greatly improved the color of the fur, we have reduced the gray hair that should be of significantly greater magnitude average after 6 week adding steviol (p<0,05, Figure 2b).

Immediately after photographing the mice were sacrificed, and collected the blood.

Example 3

The correlation between the level of free steviol in the plasma and phenotypic evaluation

Plasma samples were stored at -80°C prior to their fence for extraction and sample preparation. "Free" (aglionby) substances extracted from samples of plasma/serum by using extraction buffer (50 µl ammonium acetate (10 mm), added to 400 μl of ethyl acetate). The organic phase is evaporated and the dried residue was reconstituted in mobile phase. Was carried out by chromatographic separation using a high-speed Agilent quadrupole mass spectrometer equipped with Agilent 1100 LC system on the RP-amide column (3 µm, 100×2.1 mm) with a gradient (A: 20 mm ammonium acetate and 0.1% acetic acid in water. In:

a 0.1% acetic acid in acetonitrile; 20% (to withstand 2 min) to 100% In 18 min (to withstand 2 min), then post-run 2 min, run time 24 min. Mass spectrometric detection was performed with negative elektrorazpredelenie ionization in SIM mode (317 m/z). Identification and quantification was performed using the relative�enforcement standards steviol.

The correlation between the concentration of steviol in the plasma and improve the phenotype was assessed using Prism 5 (GraphPad Software, La Jolla, CA, USA). The results are presented in Figure 3.

Example 4

The growth of the hair follicle of a person

The human hair follicles were obtained from fragments of human skin (obtained during plastic surgery) and were grown in enriched medium William's E, containing penicillin/streptomycin, L-glutamine (2 mm/l), insulin (10 μg/ml) and hydrocortisone (8 nm/l). The growth of the hair follicle was assessed by the length (at 0, 4 and 7 day). As a positive control was used triodothyronine (T3, 30 µm/l). In parallel, we determined the effect of steviol (with a 0.625-5 mg/ml). On the 7th day of the hair follicle is exposed to different influences (control, T3, of steviol), extracted RNA (RNA). RNA was processed for Affymetrix DNA microanalysis to identify the influence of nutrients on gene expression. In suitable cases, quantify RNA expression using RT-PCR, using instruments ABI 7900 Taqman. For all procedures strictly followed the protocols suggested by the manufacturers.

Results

The effect on the growth of the follicle: the steviol dose-dependent manner conducive to the elongation of the hair follicle (table 2, bottom). At low concentrations the effect was significant, whereas at higher concentrations it Conn�will not influence significantly on the rise.

Table 2
ProcessingConcentrationGrowth (% from control)A value of p
Control100-
Triiodothyronine30 µm133<0.01
Of steviolof 0.625 mg/ml1220,1
Of steviol1,25 mg/ml121<0,1
Of steviol2.5 mg/ml113Slightly
Of steviol5 mcg/ml117Slightly

Influence on gene expression

Global effects of steviol on the expression of the gene was determined by the method of transcriptomic, i.e. micromatrix DNA analysis.

The obtained data were processed using PR�software Genedata. Thus was obtained a list of genes that had significantly different levels of expression in treated Saviola the hair follicles (compared to untreated hair follicles). Examples of genes that were differently stimulated Saviola and are included in epidermal physiology, are shown in Table 3. Lists only genes directly or indirectly involved in the proliferation or differentiation of the epidermis, and which stimulated at least twice. Thus, another aspect of this invention is a method of stimulating at least one gene listed in Table 3, containing the typed of steviol and demonstrating the effect of hair growth.

Table 3
GeneThe ratio of treated Saviola/unhandledA value of p
Transmembrane protein with EGF-like and two follistatin-like domains 23,100,0001
Fibroblastic growth factor 7 (a growth factor for keratinocytes)2,910,0006
CASP8 and ADD-like regulator of apoptosis of 2.58of 0.0004
Topoisomerase (DNA) II alpha 170 kDa2,45of 0.0004
TIMP inhibitor of metalloproteinases 32,320,0001
The chemokine (C-X-C motif) ligand 12 (stromal proishodiashie from the cell factor 1)2,220,0005
Integrin, alpha 62,15of 0.0004
Collagen, type IV, alpha 62,040,0008
Insulin-like receptor growth factor2,000,001

Genes regulated by Saviola were then mapped to biological pathways using statistical methods provided by the software Genedata (Figure 4): modulated Saviola gene expression ways of development of the epidermis, ectodermic and differentiation of keratinocytes with high statistical confidence (indicated by the p value in Table 3), and other pathways were not significantly affected. These data correspond to the observed effect of steviol n� elongation of the hair follicle (Cm. Table 2) and confirm the fact that of steviol modulates molecular pathways leading to changes in hair growth.

The mRNA level of some gene markers involved in the growth and/or differentiation of skin cells and hair follicles, were determined using RT-PCR (See Table 4).

Table 4
GeneTreatment of the hair follicle (concentration)The relative change (compared to control)
All genesControl (untreated)1
Keratin 6Of steviol (10 µg/ml)1,33±0,11
COX-2Of steviol (1,25 µg/ml)0,46±0,17
Integrin alpha 6Of steviol (0,b µg/ml)1,62±0,06
BUT-1Of steviol (1,25 µg/ml)0,64±0,08
InvolucrinOf steviol (1,25 µg/ml)0,51±0,22

The role of these genes in the development of the epidemic�of rmis and, accordingly, the development of hair is described and considered in detail, for example, Adriani et al. J. Invest Dermatol 120:923-931 ((2003); Grochot-Preczek et al. Thromb Haemost 104 (on-line 10-June 2010); Li et al. Exp Dermat 9:431-438 (2000); Ma et al. Ann Acad Med Singapore 33:784-8 (2004); Neufang et al. Proc Nat Acad Sci (USA) 98:7629-7634 (2001). Thus, another aspect of this invention is a method of stimulating associated with the development of the hair gene selected from the group consisting of Keratin 6 or Integrin alpha-6 or both, including the introduction of steviol and monitoring the growth of hair. Another aspect of this invention is a method of inhibiting COX-2 (involved in inflammation) and/or BUT-1 (involved in oxidation), including the introduction of steviol and monitoring the growth of hair.

Example 5

Effect on the skin of mice

The effect of steviol on gene expression was also analyzed in whole mouse skin (also contains hair follicles). For this, mice were kept on normal diet or a diet enriched with Saviola (see also above the corresponding data). After 8 weeks of maintenance on a diet with Saviola mice are sacrificed, the skin was isolated and freed from hair. Conducted RT-PCR for selected genes using the same technique as was described for hair follicles (see above). Surprisingly, we found the same changes of the expression level of some genes that have been observed in physiology�GII and homeostasis of the skin. They are listed in Table 5.

The role of these genes in the biology of skin was shown Pirila et al. Wound Repair & Regeneration 151:47-5 7(2007); Varani et al. Brit. J Cancer 82:657-665(2000); Fisher et al. J. Invest Dermatol. 117:219-26 (2001); Kaesler et al. Cytokine 17:157-163 (2002); Tanabe et al. J Dermatol Sci 43: 210-213 (2006); Schmutt et al. Horm Metab Res 39:96-105 (2007) matrix metalloproteinases, chemokines, interleukin PPAR, respectively.

Table 5
GeneDietary Supplement% of control (based on multiples of changes)
Any gene-100
MMP-8of steviol73±23
MMP-13of steviol53±9
SHSof steviol132±50
IL-6of steviol130±31
PPAR-5of steviol60±37

MMP-8 and MMP-13 have collagenase activity. Thus, another aspect of this invention is a method for reducing the activity of the� MMP-8 and MMP-13, including the introduction of steviol and monitoring improved appearance of hair and/or skin.

Example 6

Tablet

Of steviol150 mg
Microcrystalline cellulose300 mg
Lactose300 mg
Polyplasdone10 mg
IU-stearate2.5 mg
Si022.5 mg

Of steviol, microcrystalline cellulose and SiO2were mixed in a mixer for 10 min. Then added the lactose, and the composition was stirred for 10 minutes. Polyplasdone combined with other ingredients and stirred for 10 minutes. Finally, Mg-stearate were combined with the other ingredients and stirred for a further 2 minutes. The mixture was pressed into tablets. Took one tablet daily in the morning with Breakfast.

Example 7

Preparation of hard gelatin capsules

IngredientAmount per capsule
Of steviol100 mg
Lactose295 mg
SiO25 mg

Of steviol, lactose and SiO2were mixed in a mixer for 15 minutes and then filled with a mixture of capsules.

When hair loss adults can take two capsules a day for 3 months. If required, the dose may be increased to three capsules per day. To support hair growth at a constant level and to prevent the thinning and graying of hair can regularly take 1 capsule.

Example 8

Cooking instant flavored soft drink

IngredientAmount (g)
Of steviol0,5
Sucrose, fine powder763,1
Ascorbic acid, fine powder2,0
Citric acid anhydrous powder55,0
Lemon flavour8,0
The trisodium citrate anhydrous powder6,0
Tricalcium phosphate 5,0
B-carotene 1%CWS from DNP AG, Kaiseraugst, Switzerland0,4
Total quantity840

All the ingredients were mixed and sieved through a 500 μm sieve. The resulting powder was placed in a suitable container and mixed in a blender for at least 20 minutes. For cooking drinking 105 g of the obtained mixed powder was mixed with water to obtain 1 liter of the drink.

Ready to use soft drink contains 15 mg of enriched extract of steviol per serving (250 ml). To maintain regular hair growth can drink 2 doses a day.

Example 9

Preparation of enriched nespechennogo grain bar

IngredientAmount (g)
Of steviol0,3
Water54,0
Sol1,5
Glucose syrup130,0
Inverted sugar syrup95,0
Syrup of sorbitol35,0
Fat from palm seed60,0
Fat for frying40,0
Lecithin1,7
The hardened palm oil2,5
Dried and sliced apples63,0
Cereal100,0
Rice crispies120,0
Wheat crispies90.0
Roasted nuts40,0
Skim milk45,0
Apple flavor 74863-332,0
Citric acid5,0
Total quantity885

Enriched of steviol pre-mixed with skimmed milk powder and placed in a planetary bowl mixer. Added cereal and rice cereal, and all gently stirred. Then added chopped dried apples. Within the vessel is mixed with the water and salt in these you�e quantities (solution 1). In the second vessel were mixed syrups from glucose, invert sugar and sorbitol in the above quantities (solution 2). Fatty phase comprises a mixture of fat for baking, hardened palm oil, lecithin and emulsifier. Solution 1 was heated to 110°C. Solution 2 was heated to 113°C and then cooled in a bath of cold water. Then combined solutions 1 and 2. To a mixture of sugar solution and fat added Apple flavor and citric acid. The liquid mass was added to the dry ingredients and well mixed in a planetary bowl mixer. The mass was laid out on the marble plaque and rotated to a desired thickness. The mass was cooled to room temperature and cut into pieces. Neicey grain bar contains 10 mg steviol per serving (30 g). For sustained good health and hair growth you can eat 1-2 servings a day.

Example 10

Dry dog food containing the steviol

Basic commercial food for dogs (e.g. Mera Dog "Broken", MERA-Tiemahrung GMbH, Marienstraube 80-84, D-47625 Kevelayer-Wetten, Germany) are sprayed with a solution of stevia extract in water, together with antioxidants such as vitamin C (e.g. ROVIMIX ®C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) and their derivatives, i.e. sodium of ascorbyl the monophosphate (e.g. STAY-C ® 35 from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) in an amount sufficient for the introduction of the dog on a daily dose of 4 mg�aviola per kg of live weight. Food composition was dried to 90% by weight of the dry matter content. Food for dogs with average weight of 10 kg, receiving approximately 200 g of dry food per day, contains approximately 200 mg steviol per kg of feed. For dogs with more weight food mixture is prepared accordingly.

For continuous improvement in the skins of dogs giving her dry food containing of steviol, daily, depending on season, for example, in the winter, or under special conditions, for example, prior to the show, animals can be given treats or capsules containing the steviol, 2-3 times a day for several weeks to increase the dose.

Example 11

Moist food for cats, containing the steviol

The main commercial cat food (eg. Happy Cat "Adult", Tierfeinnahrung, Sudliche Hauptstraube 38, D-86517 Wehringen, Germany) is mixed with a solution of stevia extract in water, together with antioxidants such as vitamin C (e.g. ROVIMIX® C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) and their derivatives, i.e. sodium of ascorbyl the monophosphate (e.g. STAY-C ® 35 from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) or a mixture of tri-, di - and monophosphate esters of sodium/calcium L-ascorbate (e.g., ROVIMIX® C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) in an amount sufficient to introduce the cat 4 mg steviol per kg of live weight. Food for cats with an average weight of 5 kg, receiving approximately 400 g of wet food in �tier, contains approximately 50 mg steviol per kg of feed. Food composition is dried to 90% by weight of the dry matter content.

For continuous improvement of skinning cats give her dry food containing of steviol, on a daily basis. Depending on the season, for example, in the winter, or under special conditions, for example, prior to the show, animals can give them treats or capsules containing the steviol, 2-3 times a day for several weeks to increase the dose.

Example 12

Lacmta for dogs containing the steviol

Commercial treats for dogs (e.g. Mera Dog "Biscuit" for dogs as supplied by MERA-Tiemahrung GMbH, Marienstraube 80-84, D-47625 Kevelayer-Wetten, Germany) are sprayed with a solution of stevia extract in water, together with antioxidants such as vitamin C (e.g. ROVIMIX ®C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) and their derivatives, i.e. sodium of ascorbyl the monophosphate (e.g. STAY-C ® 50 from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) or a mixture of tri-, di - and mono-phosphate esters of sodium/calcium L-ascorbate (e.g. ROVIMIX® C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) in an amount sufficient for the introduction of the delicacy of 0.5-5 mg steviol per g treats. Food composition is dried to 90% by weight of the dry matter content. To reduce hair loss and graying of the treat can be given 2-3 times a day either alone or as a Supplement to the daily feeding,containing the steviol. This can also be done prior to the indications for increasing the dose and preparation of shiny glossy skins.

Example 13

Treats for cats, containing an extract of Stevia

Commercial cat treats (such as Whiskas Dentabits for cats supplied Whiskas, Masterfoods GmbH, Eitzer Str. 215, 27283 Verden/Aller, Germany) are sprayed with an aqueous solution of Stevia extract, together with antioxidants such as vitamin C (e.g. ROVIMIX® C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) and their derivatives, i.e. sodium of ascorbyl monophosphate (e.g. STAY-C ® 35 from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) or a mixture of tri-, di - and monophosphate esters of sodium/calcium L-ascorbate (e.g. ROVIMIX® C-EC from DSM Nutritional Products Ltd, Kaiseraugst, Switzerland) in an amount sufficient for the introduction treats of 0.5-5 mg steviol per g treats. Food composition is dried to 90% by weight of the dry matter content. You can give 2 to 4 servings of sweets per day.

1. The use of steviol in the production of oral nutraceutical composition or food composition for improving the appearance of hair/fur/feathers/scales of animals.

2. The use according to claim 1, where the use is permanent.

3. The use according to claim 1, where the improvement is a hair color restoration/fur and/or delay graying of the hair/fur.

4. The use according to claim 1, wherein the improvement is selected from: reduce hair loss, restoring hair growth after� baldness, increasing the thickness of hair, obstruction associated with age to a thinning of the hair, prevent premature hair loss, or delay or reduce the degree associated with age of hair loss and thinning.

5. The use according to claim 1, wherein the animal is a mammal.

6. The use according to claim 5, where the mammal is a human.

7. The use according to claim 5, where the mammal is a dog or cat.



 

Same patents:

FIELD: medicine.

SUBSTANCE: device comprises a driving part, a cartridge body and a tip. The driving part comprises a drive and a movable push rod. The cartridge body is configured to comprise a high-viscosity surgical adhesive cartridge. The tip is detachably connected to the cartridge body and comprises two or more passes and two or more tubular elements. At least a portion of each of the two or more tubular elements is integrated into the passes. The tubular elements are configured so that to enable moving the high-viscosity surgical adhesive from the cartridge to the surface of an anatomic tissue, when the user actuates the above drive.

EFFECT: device enables delivering the high-viscosity fluid adhesive during the surgical procedure to a place of use onto the flat surface of tissue.

45 cl, 27 dwg

FIELD: instrument making.

SUBSTANCE: invention relates to systems for intravenous injection of radiopharmaceuticals (RP) from a generator and can be used in diagnostics of myocardial perfusion and cancer diseases by means of a positron emission tomography method. The system includes a generator with input and output fittings, a control unit, and an injection pump, an eluent tank, four three-way valves, pipelines, pressure and radioactivity sensors, sterilising filters, a unidirectional valve, a syringe and a catheter for intravenous infusion. The generator has input and output holes, the first of the three-way valves is connected to the eluent tank and to an elution pump, the second one is fixed on the output fitting of the generator, connected to an eluate conveying pipeline, and its end is provided with the second sterilising filter and the third three-way valve connected to the unidirectional valve, to the catheter for intravenous infusion and the syringe. The sterilising filters are equipped with built-in air valves, the pressure sensor is installed between the first three-way valve and the first sterilising filter, the radioactivity filter is installed before the second sterilising filter, the fourth three-way valve is located on the input fitting of the generator, and the unidirectional valve is located between the second sterilising filter and the third three-way valve. The control unit can control the elution pump, 1, 2 and 4 three-way valves and monitor the pressure and radioactivity sensors. The system allows measuring an activity of a preparation immediately at its injection to a patient, provides the injection of the required preparation dose in an automatic mode, ensures the assessment of the state of a sorbent of the generator column by means of the pressure sensor, differs by a simple design and is intended for assembly directly at PET centres.

EFFECT: software allows avoiding the need for manual calculations of radioactivity at calibration of the instrument.

Cylindrical pump // 2529405

FIELD: engines and pumps.

SUBSTANCE: invention relates to medical pumps. Cylindrical pump comprises cylindrical top case accommodating top rotor and cylindrical bottom case engaged with top case to accommodate bottom rotor engaged with top rotor. Inner wall of top case and top rotor lower outer circle and bottom case inner wall and rotor upper outer surface make the integral tubular cylinder. Top and bottom rotors comprise plungers fitted thereon to spin in tubular cylinder with closed ends. Cylinder is equipped with inlet pipe and discharge pipe for liquid medical preparation extending beyond outer circles of said top and bottom cases. Top and bottom rotors are engaged to run independently.

EFFECT: simplified design, stable feed irrespective of source vessel location height.

11 cl, 22 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to devices of a medication introduction for introduction of a medication into a human or an animal body, in particular, but not exclusively, to devices, which have a detachable cartridge with a medication. The device of a medication introduction contains a case, a telescopic piston rod assembly for bringing in motion a plug of a reservoir with a medication; and a drive mechanism for the telescopic piston rod assembly. The telescopic piston rod assembly has a drive shaft, telescopically connected to the piston for bringing the plug in motion via an intermediate connection link. The intermediate connection link contains the first and second elements, telescopically connected to each other, a piston, telescopically connected to one of the first and second elements; and a keyed connection for restriction of the piston rotation relative to the case. When the drive mechanism brings the drive shaft in motion, the piston, the first and second elements and the drive shaft telescopically move forward or backward relative to each other.

EFFECT: invention provides the more compact device construction.

12 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to devices for subcutaneous injections. The device comprises a body, a liquid container having an opened end and an applicator in the form of a drug cartridge having a first primary surface comprising a microneedle matrix, a liquid canal connecting the opened end of the container with the microneedle matrix, a first pressure accumulator and a second pressure accumulator. The applicator and the container are independently integrated in the body. The first pressure accumulator can apply a force to the applicator to project it in the direction substantially perpendicular to the first primary surface. The second pressure accumulator can automatically open the opened end of the container to form a liquid connection between the opened end of the container and the liquid canal, as well as to push the liquid through the opened end of the container, liquid canal and microneedle matrix. According to the second version of the device, the body comprises a common actuator functionally connected with the first and second pressure accumulators and actuating the first and second pressure accumulators. The first pressure accumulator comprises a spring with two bases covering the container from two sides, and a segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The method involves the stages to provide the body comprising the drug cartridge with the opened end, the applicator having the first primary surface comprising the microneedle matrix, and the pressure accumulator used to apply a force to the applicator in the direction substantially perpendicular to the first primary surface. The pressure accumulator comprises the spring with two bases covering the container from two sides, and the segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The microneedle matrix is automatically moved in the direction perpendicular to the first primary surface. The opened end of the cartridge is automatically opened. The fluid connection is formed between the opened end of the cartridge and the microneedle matrix. The fluid is automatically pushed out from the drug cartridge through the opened end of the cartridge into the microneedle matrix. According to the third version, the first pressure accumulator comprises the spring with two bases covering the container from two sides, and the segment contacting the applicator. The spring is substantially U-shaped, and if unstressed, the spring is in a close proximity to the container, substantially in parallel with its longitudinal axis. The presented devices can be actuated in one movement, thereby providing automatic and reliable patient's skin needling by the microneedle matrix and then automatic release and cutaneous introduction of the liquid placed into the ready-to-use drug cartridge in a controlled mode that provides the adequate digestion of this liquid.

EFFECT: effective delivery of a wide variety of the liquids meeting the user's demands and dosage individual for each specific patients can be achieved by the relatively injury-free method with a minimised probability of hollow microneedle displacement in skin penetration and the amount of the liquid remained in the device after introduction into the patient.

35 cl, 33 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely systems for infusion of radiopharmaceuticals into patients for the purpose of diagnosis of a wide range of diseases by positron-emission tomography. The system comprises a rubidium-82 generator, an eluent container connected through a first T-valve with a pump for generator elution and with a sterilising filter through a pipe line, with an input fitting of the generator. A second T-valve is mounted on an output fitting of the generator; it is connected with the pipe line. A free output of the valve is connected with a disposable syringe filled with the eluent. A third T-valve connected with a non-return valve with an intravenous infusion catheter is coupled with a free end of the pipe line through the sterilising filter; a free end of the valve is coupled with a disposable syringe filled with the eluent.

EFFECT: invention provides higher anti-embolism patient's safety with maintaining eluent supply rate.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely traumatology and orthopaedics, and is applicable for the purpose of treating the patients suffering postoperative and posttraumatic acute knee sinovitis. That is ensured by irrigation of the knee joint cavity with 1.38% isotonic sodium carbonate cooled to temperature +5°C. It is followed by introducing a medicated mixture 3 ml containing 5% ascorbic acid for injections, 5% unitiol for injections and 0.5% Novocaine for injections taken in equal proportions.

EFFECT: method provides reducing length of treatment of said pathology ensured by local intra-articular therapy enabling intra-articular homeostasis recovery due to differently-directed action of the mixture ingredients.

7 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to medical injectors with front loading and syringes, syringe interfaces, syringe plungers and adaptors for application with novel or existing medical injectors, in which syringe of special construction is made with possibility to be installed into injector and to be released from injector by means of split mechanism. Syringe for application with injector connects syringe-holding mechanism, which contains flexible ring. Syringe contains case, plunger, movably placed in case; at least one fastening element, connected with case. At least one fastening element interacts with flexible ring of syringe-holding mechanism for split fixation of syringe to injector. At least one releasing element is made with possibility to deform flexible ring in order to ensure syringe release from fastener to injector when syringe rotates around its axis with respect to injector. At least one releasing element is located in axial direction before at least one fastening element. Injector for injecting liquid from installed on it syringe contains case, drive element at least partly located in case and made with possibility of engagement with plunger, located inside syringe, and syringe-holding mechanism. Syringe-holding mechanism is connected with case and is made with possibility to intake syringe when it is moving axially backward with respect to syringe-holding mechanism irrespective of orientation of syringe around its axis. Syringe-holding mechanism in fact consists of flexible ring, held in fixed axial position in syringe-holding mechanism. In second version of injector implementation drive element contains flexible ring, located on it for engagement with plunger, located inside syringe. Flexible ring in first state is adapted for engagement with plunger and formation of connection with it, when plunger is turned around its axis into first position. Flexible ring, deformed to second state, is adapted for plunger release, when plunger is turned around its axis into second position. Syringe for application with injector, which contains syringe-holding mechanism. Syringe contains case, plunger, movably placed in case, and at least one fastening element, connected with case. At least one fastening element contains flexible ring, made with possibility of split fixation of syringe to injector.

EFFECT: invention allows to connect syringe with injector easily without taking into account specific orientation of syringe and/or syringe plunger.

16 cl, 7 dwg

Unit-dose syringe // 2392009

FIELD: medicine.

SUBSTANCE: invention belongs to syringe-devises and can be applied in medicine, engineering, defence, building, maintenance, household. Unit dose syringe containing solution-composition, and device for content's delivery from unit-dose syringe. It is designed in form of sleeve made of film or foil or foiled film fixed on sleeve's entrance and exit to truncated cups-covers with nozzles of unit-dose syringe filling, and to cup of injection-needle or aerosol valve, or nozzle, and placed with slid fit into cylindrical barrel-container.

EFFECT: application field of unit dose syringe expands, reliability rises.

5 cl

FIELD: medicine, stomatology.

SUBSTANCE: the present innovation deals with applying the methods of local anesthesia and could be applied at anesthetization of mandibular teeth. Due to palpation one should detect the most deepened site in area of anterior edge of mandibular branch. Then with the help of a syringe supplied with a needle of semi-oval shape it is necessary to puncture oral mucosa just into area of mandibular lingual followed by introducing the anesthetic. The innovation enables to avoid the traumas of fascia and a tendon of temporal and pterygoid muscles due to excluding the contact with the bone and oval shape of the needle and, also, achieve adequate anesthetization from the first time.

EFFECT: higher efficiency.

1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering a homeopathic agent. The agent "Liarsin" is used, which is administered subcutaneously before calving into the biologically active points in the centre of the front and rear udder parts.

EFFECT: invention is highly effective for prevention of parturient paresis in cows.

4 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of obtaining microcapsules of medication, which possess supermolecular properties, by method of precipitation with non-solvent, characterized by the fact that as medication applied is powder of unabi berries, preliminarily dissolved in butanol, as envelope - carrageenan, which is precipitated from solution in acetone by addition as non-solvent of ethanol and water, with the following drying at room temperature.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of output by weight).

2 ex, 18 dwg

FIELD: medicine.

SUBSTANCE: method includes the preparation of a carious cavity, opening the tooth cavity, creation of an access to root canals, extension of their orifice. Removal of a decayed material from the root canals and their drug treatment are carried out. After that, performed are: wide opening of the apical tooth orifice, mechanical and drug removal of periapical pathological exudative formations in the focus of periapical inflammation through the root canal. Before filling the canal with a filling material the gel "Lamifaren" is introduced into the focus of periapical destruction. Such introduction is performed three times after a day under temporary stopping. The gel "Lamifaren" is introduced inside in a dose of 50 g 2 times per day for 30 days.

EFFECT: application of the invention accelerates bone tissue regeneration due to the active release of an active substance calcium alginate, provides stable remission due to local and systemic detoxifying effect.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of purification and health improvement of an organism. For this purpose therapeutic starvation for not fewer than 5 days in case of a 7-day programme and for not fewer than 7 days in case of a 9-day programme is carried out. The duration of a recovery period constitutes two days. Food intake is realised nine times per day each day both in the process of therapeutic starvation and in the recovery period. In the period of therapeutic starvation the first food intake includes bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "APITOK" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The second food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The third food intake supposes an intake of bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The fourth food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The fifth food intake consists of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The sixth food intake consists of bee products "APIGRANULES 2" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and one glass of still mineral water. The seventh food intake includes tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The eighth food intake supposes an intake of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The ninth intake of food includes depressant tea, including mint grass, valerian root, fennel seeds, cumin seeds, epilobium or strawberry leaves and one glass of apple-carrot juice. In the recovery period in 1-st, 2-nd, 3-rd, 4-th and 6-th intakes of food the composition of products remains the same as in the process of starvation. For the fifth intake of food the patients take tea black or green with ginger, one teaspoon of honey and vegetable soup. For the seventh intake of food the patients take tea black or green with ginger, "MILK COCKTAIL WITH CHITOSAN". The eighth intake of food includes tea black or green with ginger, one teaspoon of honey, "APICAMPA" cereal. The ninth intake of food for the recovery period includes a baked apple, depressant tea. In addition, a number of procedures are carried out after each food intake during the period of therapeutic starvation and the recovery period. After the first food intake gymnastics "5 Tibetan pearls" is realised. After the second food intake exercises on training apparatuses, procedures of press-therapy, electrolypolysis and myostimulation are realised. After the third food intake exercises of therapeutic physical training or aerobics are performed. After the fourth food intake a rest in form of a walk, a halotherapy session, combined with a session of relaxation therapy are realised. After the fifth food intake a course of strip-plastic is carried out. After the sixth food intake massage by manual application with a peloid-based mixture or manual massage with honey is carried out. After the seventh food intake an infra-red sauna, shower, phytobath with medicinal herbs, honey, ginger, lemon juice is taken. After the eighth food intake a shower is taken.

EFFECT: method ensures effective health improvement of the organism with the preservation of the full value life style and a sense of a comfortable state in the starvation period, reduction of recovery period term after starvation, purification of the organism without loading on the gastrointestinal tract, weight loss, and improvement of the general state and workability of the patients.

3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.

EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.

4 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to versions of cationic polyelectrolytic composition for application in personal care products and household chemicals and method of its obtaining. Composition includes: 1) cationic synthetic water-soluble polyelectrolyte, which contains (meth)acrylamide polymer and one or several of the following substances: I) cationic (meth)acrylamide monomer, and II) cationic monomer of (meth)acrylic acid, and III) hydrolysis-resistant cationic monomers, where polyelectrolyte has weight average molecular weight from approximately 10000 to approximately 2000000, charge density from, 0.001 to 2.5 meq./g, and level of acrylamide monomer that did not react constitutes less than 50 ppm, 2) surface-active substance and 3) solvent.

EFFECT: preparations, obtained on the base of composition, possess higher transparency.

17 cl, 3 dwg, 12 tbl, 106 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing shea oil microcapsules. Said method is characterised by that shea oil is dissolved in dimethyl sulphoxide, the obtained mixture is dispersed in a suspension of sodium alginate in butanol in the presence of E472c, followed by addition of isopropanol and water, filtering and drying the obtained suspension of microcapsules, wherein the nucleus/polymer ratio in the microcapsules is 1:1 or 1:3.

EFFECT: invention provides a simple and fast process of producing shea oil microcapsules and increases mass output.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to using medicinal plant Gelsemium elegans Benth. and Datura metel L. blossom in preparing a therapeutic agent for eliminating or relieving acute and persistent withdrawal symptoms caused by taking a dependence-producing substance. The invention refers to pharmaceutical compositions (versions) for eliminating or relieving acute or persistent withdrawal symptoms caused by taking the dependence-producing substance, and containing Gelsemium elegans Benth. and Datura metel L. blossom in certain relations.

EFFECT: pharmaceutical compositions containing Gelsemium elegans Benth and Datura metel L. blossom are effective for the individuals suffering drug dependence.

15 cl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of simultaneous obtaining of two flavonoids - patuletine and its 7-O-β-D-glucopyranoside - patuletrine. Method consists in the following: milled edge petals of flower of high flavonoid sorts of tagetes patula are extracted with hexane, dried and r-extracted with chloroform, chloroform extract is concentrated, dry residue is dissolved in mixture of petroleum ether - chloroform, precipitated sediment is filtered, washed with petroleum ether and dried, obtained dry powder is dissolved in mixture chloroform - ethanol, precipitated sediment is filtered, washed with petroleum ether and dried with obtaining patuletine. Then, extraction of raw material, which remains after chloroform processing, is carried out with ethanol, alcohol extract is filtered and concentrated, after that, water residue is subjected to liquid phase extraction with ethylacetate, then, organic layer is concentrated, dry residue is dissolved in mixture chloroform - ethylacetate, precipitated sediment is filtered, washed with cooled ethylacetate, solution of hydrochloric acid in ethanol, ethanol and ethylacetate and dried, dry powder is dissolved in mixture ethylacetate-ethanol, precipitated sediment is filtered, washed with ethylacetate and dried with obtaining patuletrine.

EFFECT: method makes it possible to obtain highly pure samples of patuletine and patuletrine, as well as increase target product output.

4 dwg, 3 tbl, 4 ex

FIELD: food industry.

SUBSTANCE: imitator of odour of hallucinogenic plant i.e. Hawaiian baby woodrose for sniffer dogs training contains an inert carrier and an odour substance; the imitator is specifically as follows: the odour substance is represented by a mixture containing benzoic acid and "rose" food flavouring agent.

EFFECT: sniffer dogs preparation for the said hallucinogenic substance search.

6 cl, 7 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!